GSK/$GSK
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About GSK
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Ticker
$GSK
Sector
Primary listing
NYSE
Employees
68,629
Headquarters
Website
GSK Metrics
BasicAdvanced
$94B
27.06
$1.73
0.23
$1.62
3.61%
Price and volume
Market cap
$94B
Beta
0.23
52-week high
$47.16
52-week low
$31.72
Average daily volume
6.4M
Dividend rate
$1.62
Financial strength
Current ratio
0.836
Quick ratio
0.544
Long term debt to equity
94.553
Total debt to equity
112.684
Dividend payout ratio (TTM)
46.05%
Interest coverage (TTM)
10.96%
Profitability
EBITDA (TTM)
12,397.546
Gross margin (TTM)
72.43%
Net profit margin (TTM)
17.08%
Operating margin (TTM)
21.17%
Effective tax rate (TTM)
13.56%
Revenue per employee (TTM)
$612,120
Management effectiveness
Return on assets (TTM)
7.13%
Return on equity (TTM)
41.52%
Valuation
Price to earnings (TTM)
27.056
Price to revenue (TTM)
4.545
Price to book
4.14
Price to tangible book (TTM)
-9.2
Price to free cash flow (TTM)
30.367
Free cash flow yield (TTM)
3.29%
Free cash flow per share (TTM)
1.542
Dividend yield (TTM)
3.46%
Forward dividend yield
3.61%
Growth
Revenue change (TTM)
2.73%
Earnings per share change (TTM)
118.57%
3-year revenue growth (CAGR)
3.49%
10-year revenue growth (CAGR)
3.05%
3-year earnings per share growth (CAGR)
-27.49%
10-year earnings per share growth (CAGR)
-6.22%
3-year dividend per share growth (CAGR)
-5.67%
10-year dividend per share growth (CAGR)
-4.36%
What the Analysts think about GSK
Analyst ratings (Buy, Hold, Sell) for GSK stock.
Bulls say / Bears say
GSK reported a 37% rise in Q2 2025 pre-tax profit driven by robust oncology and specialty medicines sales, with revenue up 6% to nearly £8 billion and core EPS up 15%, and forecasts now at the top end of guidance for FY2025 (FT).
A $500 million licensing deal with Jiangsu Hengrui Pharmaceuticals grants GSK global rights to HRS-9821 and 11 early-stage programs in COPD, oncology, immunology and inflammation, significantly bolstering its specialty pipeline (Reuters).
The price of GSK’s Mosquirix malaria vaccine will be halved to below $5 per dose by 2028 through a partnership with Bharat Biotech, expanding access across 12 African nations and strengthening GSK’s vaccines revenue potential and global health profile (Reuters).
Vaccine sales have slumped, with Arexvy generating only £0.1 billion in Q1 2025—a 57% year-on-year decline—underscoring short-term pressure on GSK’s vaccines segment and its impact on growth forecasts (Reuters).
Regulatory uncertainty around Blenrep in the U.S. persists after an FDA advisory committee voted against it, potentially delaying a key multiple myeloma launch and capping projected peak sales of at least £3 billion (FT).
Intensifying competition in the RSV vaccine market from Pfizer’s Abrysvo and Moderna’s mRESVIA threatens Arexvy’s market share; GSK’s FDA expansion bid faces a tough review amid these headwinds (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 1 Nov 2025.
GSK Financial Performance
Revenues and expenses
GSK Earnings Performance
Company profitability
GSK News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for GSK stock?
GSK (GSK) has a market cap of $94B as of November 05, 2025.
What is the P/E ratio for GSK stock?
The price to earnings (P/E) ratio for GSK (GSK) stock is 27.06 as of November 05, 2025.
Does GSK stock pay dividends?
Yes, the GSK (GSK) stock pays dividends to shareholders. As of November 05, 2025, the dividend rate is $1.61919 and the yield is 3.61%. GSK has a payout ratio of 46.05% on a trailing twelve-month basis.
When is the next GSK dividend payment date?
The next GSK (GSK) dividend payment is scheduled for January 08, 2026.
What is the beta indicator for GSK?
GSK (GSK) has a beta rating of 0.23. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.